Hematocrit levels and hospitalization risks in hemodialysis patients

Journal of the American Society of Nephrology

Volumn 10, Issue 6, 1999, Pages 1309-1316

  Xia, Hong ^a   Ebben, Jim ^a   Ma, Jennie Z ^b   Collins, Allan J ^a,b  

^a MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEMATOCRIT; HEMODIALYSIS PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

EID: 0032991310     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Adamson JW, Eschbach JW: Management of the anaemia of chronic renal failure with recombinant erythropoietin. Q J Med New Series 73: 1093-1101, 1989
2. Muirhcad N, Hodsman AB: Occult infection and resistance of anaemia to rHuEpo therapy in renal failure. Nephrol Dial Transplant 5: 232-234, 1990
3. Almond MK, Tailor D, Marsh RP, Raftery MJ, Cunningham J: Increased erythropoietin requirements in patients with failed renal transplants returning to a dialysis programme. Nephrol Dial Transplant 9: 270-273, 1994
4. Drueke TB: R-HuEPO hyporesponsiveness: Who and why? Nephrol Dial Transplant 10: 62-68, 1995
5. Douglas SW, Adamson JW: The anemia of chronic disorders: Studies of marrow regulation and iron metabolism. Blood 45: 55-65, 1975
6. Hymes LC, Hawthorne SM, Clowers BM: Impaired response to recombinant erythropoietin therapy in children with peritonitis. Dial Transplant 23: 462-463, 1994
7. Danielson B: R-HuEPO hyporesponsiveness: Who and why? Nephrol Dial Transplant 10: 69-73, 1995
8. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: Results of a combined phase I and II clinical trial. N Engl J Med 316: 73-78, 1987
9. Rao DS, Shih MS, Mohini R: Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 328: 171-175, 1993
10. Tomson CR, Edmunds ME, Chambers K, Bricknell S, Feehally J, Walls J: Effect of recombinant human erythropoietin on erythropoiesis in homozygous sickle-cell anaemia and renal failure. Nephrol Dial Transplant 7: 817-821, 1992
11. Cheng IKP, Lu H, Wei DCC, Cheng S, Chan C, Lee FCP: Influence of thalassemia on the response to recombinant human erythropoietin in dialysis patients. Am J Nephrol 13: 142-148, 1993
12. Lai KN, Wong KC, Li PKT, Lui SF: Use of recombinant erythropoietin in thalassemic patients on dialysis. Am J Kidney Dis 19: 239-245, 1992
13. Madore F, Bridges K, Brugnara NL, Lew NL, Lowrie EG, Lazarus JM, Owen WF: A population study of the interplay between iron, nutrition, and inflammation in erythropoiesis in hemodialysis patients [Abstract]. J Am Soc Nephrol 7: 1456, 1996
14. Siimes MA, Ronnholm KAR, Antikainen M, Holmberg C: Factors limiting the erythropoietin response in rapidly growing infants with congenital nephrosis on a peritoneal dialysis regimen after nephrectomy. J Pediatr 120: 44-48, 1992
15. Collins AJ, Ma J, Constantini E, Everson S: Dialysis unit and patient characteristics associated with reuse practices and mortality. 1989-1993. J Am Soc Nephrol 9: 2108-2117, 1998
16. Cox D: Regression models and life-tables. J Roy Statistical Soc Series B 34: 187-220, 1972
17. Andersen PK, Borgan O, Gill RD, Keiding N: Statistical Models Based on Counting Processes, New York, Springer-Verlag, 1993
18. Umen AJ, Le C: Prognostic factors, models and related statistical problems in the survival of end-stage renal disease patients on hemodialysis. Stat Med 5: 637-652, 1986
19. Brookmeyer R, Gail MH: Biases in prevalent cohorts. Biometrics 43: 739-749, 1987
20. Social Security Administration: Social Security: Your Number, 1996
21. Health Care Financing Administration: Data Users Reference Guide, Baltimore, Maryland, Health Care Financing Administration, 1995
22. U.S. Renal Data System: USRDS 1997 Annual Data Report, Bethesda, Maryland, 1997
23. Ma J, Ebben J, Xia H, Collins A: Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10: 610-619, 1999
24. Eknoyan G, Levin N: Clinical Practice Guidelines: Final Guideline Summaries from the Work Groups of the National Kidney Foundation. Dialysis Outcomes Quality Initiative, New York, National Kidney Foundation, 1997
25. Churchill DN, Muirhead N, Goldstein M, Posen G, Fay W, Beecroft ML, Gorman J, Taylor DW: Effect of recombinant human erythropoietin on hospitalization of hemodialysis patients. Clin Nephrol 43: 184-188, 1995
26. Patruta SI, Edlinger R, Sunder-Plassmann G, Horl WH: Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 9: 655-663, 1998
27. Health Care Financing Administration: 1997 Annual Report, End Stage Renal Disease Core Indicators Project. Baltimore, Maryland, Department of Health and Human Services, Health Care Financing Administration Office of Clinical Standards and Quality, 1997
28. Madore F, Lowrie E, Brugnara C, Lew N, Lazarus M, Bridges K, Owen W: Anemia in hemodialysis patients: Variables affecting this outcome predictor. J Am Soc Nephrol 8: 1921-1929, 1997